Evaluating Patients' Tolerability, Toxicity Levels to CC-223 Inhibitor
the Cancer Therapy Advisor take:
The safety, tolerability, non-tolerated dosage, maximum tolerated dosage (MTD), and preliminary pharmacokinetic profile of the mammalian target of rapamycin (mTOR) inhibitor CC-223 were assessed in patients with advanced cancer, according to an article published online in the journal Cancer.
In this study, 28 patients with advanced solid tumors or multiple myeloma were administered 7.5 to 60 mg of CC-223 initially, followed by an oral daily dosage in 28-day cycles until disease progression.
Results showed hyperglycemia, fatigue, and rash were the three most common grade 3 adverse effects related to the treatment.
Furthermore, four of the patients experienced dose-limiting toxicities, including hyperglycemia, rash, fatigue, and mucositis.
The MTD was determined to be 45 mg per day and the disease control rate was 32%.
The mean terminal half-life was determined to have a range from 4.86 to 5.64 hours, using the pharmacokinetics of CC-223. Patients who received greater than or equal to 45 mg of CC-223 per day demonstrated a maximum observed plasma concentration of 269 to 480 ng per milliliter.
CC-223 greater than or equal to 30 mg per day inhibited the phosphorylation of mTORC1/mTORC2 pathway biomarkers in blood cells, with an exposure-response relationship.
Patients’ responses included one partial response (breast cancer; response duration 220 days; 30-mg/d cohort), eight with stable disease (across ≥15 mg/d cohorts; response duration range, 36-168 days), and 12 patients with progressive disease.
Profile of the mammalian target of rapamycin inhibitor CC-223 assessed in patients with advanced cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer